Polyphor In Peril After Breast Cancer Drug Failure
Shares Crash On Balixafortide Setback
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.
